|
21 |
Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
Fischer, Sarah Cornelia. - Erlangen : Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2021
|
|
|
22 |
Biosimilars in der Kinderrheumatologie
Enthalten in Kinder- und Jugendmedizin Bd. 21, 2021, Nr. 05: 339-348
|
|
|
|
23 |
Patients Retransitioning from Biosimilar TNFα Inhibitor to the Corresponding Originator After Initial Transitioning to the Biosimilar: A Systematic Review
Enthalten in BioDrugs 6.12.2021: 1-13
|
|
|
|
24 |
The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review
Enthalten in Advances in therapy 15.11.2021: 1-33
|
|
|
|
25 |
Effect of Originator Infliximab Treatment on Disease-Related Hospitalizations, Work Productivity and Activity Impairment, and Health Resource Utilization in Patients with Crohn’s Disease in a Real-Life Setting: Results of a Prospective Multicenter Study in Germany
Enthalten in Inflammatory intestinal diseases Bd. 6, 2021, Nr. 1: 48-60
|
|
|
|
26 |
Was tut ein Geschichtsschreiber?
Enthalten in Philologus Bd. 164, 2020, Nr. 2: 250-2689. 19 S.
|
|
|
|
27 |
Online validation of combined mood induction procedures
Marcusson-Clavertz, David. - Ludwig-Maximilians-Universität München, 2019
|
|
|
|
28 |
How Similar Is Biosimilar? A Comparison of Infliximab Therapeutics in Regard to Charge Variant Profile and Antigen Binding Affinity
Enthalten in Biotechnology journal Bd. 14, 2019, Nr. 4. 9 S.
|
|
|
|
29 |
Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1—Biosimilar and Originator Infliximab in the Hospital Setting
Enthalten in BioDrugs 3.4.2019: 1-13
|
|
|
|
30 |
Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 2—Biosimilar and Originator Etanercept in the Outpatient Setting
Enthalten in BioDrugs 3.4.2019: 1-8
|
|
Administration
